Cannabis use and diabetes may be a risky combination for people taking GLP1 receptor agonist medication, according to a large new cohort study published in Drug and Alcohol Dependence. The research links cannabis use to markedly higher rates of death, heart problems and kidney harm in this group.

Tracking Thousands of Diabetes Patients

The research drew on the TriNetX Research Network. It followed more than 614,000 adults with type 2 diabetes who began GLP1 receptor agonist therapy between January 2017 and December 2025. Notably, among this group, 4217 patients, just under one per cent of the total, had a documented cannabis related diagnosis in the two years before starting treatment.

Furthermore, researchers matched each cannabis user with a comparison patient of similar age, health status and more than 40 other clinical factors. In total, 4117 matched pairs were tracked for a median of two and a half years. The result is one of the most detailed pictures yet of how cannabis use and diabetes management interact under real world conditions.

Sharply Higher Death and Disease Risk

The findings were stark. Patients who used cannabis were 64 per cent more likely to die from any cause during the study period. They also faced a 42 per cent higher risk of major cardiovascular events such as heart attack and stroke. In addition, serious kidney complications were 55 per cent more common among cannabis users.

A clear pattern emerged around severity of use. Patients diagnosed with cannabis use disorder carried a mortality risk more than double that of non users. This is a more serious and persistent pattern of marijuana use. Meanwhile, those with lower level cannabis use still faced a risk 73 per cent higher than their matched peers. Greater exposure tracked with greater harm throughout the data. This dose response relationship strengthens the case that cannabis use and diabetes outcomes are genuinely connected, rather than linked by some unmeasured factor.

How Robust Are the Findings

Researchers also calculated E values between 2.21 and 2.63 for the main results. This statistical measure shows how strong an unmeasured confounding factor would need to be to fully explain away the associations. The figures suggest the findings on cannabis use and diabetes are reasonably robust.

GLP1 receptor agonists have become a mainstay of diabetes treatment in recent years. Clinicians prize them for lowering blood sugar while also protecting the heart and kidneys. For instance, earlier trials found these medications can cut major cardiovascular events by around 14 per cent. They reduce all cause mortality by roughly 12 per cent and lower composite kidney complications by close to 18 per cent. The new findings suggest cannabis use may blunt some of these protective effects in certain patients.

Cannabis use and diabetes have become an increasingly common pairing over the past two decades. Past month cannabis use in this population rose by around 340 per cent between 2005 and 2018. By 2022 it had reached just over 10 per cent of adults with diabetes. Broader estimates suggest roughly 180 million people worldwide aged between 15 and 64 use cannabis. Growing decriminalisation and legalisation in various places has widened both its availability and its social acceptance.

Conflicting Evidence on Heart and Kidney Health

The relationship between marijuana use and cardiovascular health has divided previous research. For example, one recent review pooled data from 24 observational studies and close to 200 million people. It linked cannabis use to a 29 per cent higher risk of acute coronary syndrome and a 20 per cent higher risk of stroke. Cardiovascular death was roughly twice as likely among cannabis users in that analysis. Yet another meta analysis of observational studies found no significant link between cannabis use and heart attack or stroke. Differences in study design, consumption patterns and populations studied can produce conflicting conclusions.

Less is known about the effect of cannabis on kidney health. The body’s endocannabinoid system, including receptors found in renal tissue, is understood to influence kidney blood flow and function. However, existing evidence in this area remains inconsistent. The authors of the new study note that theirs is the first to examine how cannabis use and diabetes treatment with GLP1 therapy interact in this way.

What It Means for Patients and Clinicians

One finding offered a measure of reassurance. Among cannabis users in the study, those also taking SGLT2 inhibitor medication had notably better outcomes. This second class of diabetes drug was linked to a 38 per cent lower risk of death and a 30 per cent lower risk of kidney complications among cannabis users. Still, the authors describe this as an exploratory finding that warrants further investigation rather than a settled clinical recommendation.

The study’s authors are urging clinicians to ask patients about cannabis use when prescribing GLP1 medication. They recommend factoring this into conversations about risk. Cannabis use and diabetes are likely to intersect more often in the years ahead, given rising rates of both. Understanding how the two interact with widely used treatments is likely to remain an important area of research.

The study relied on diagnostic codes to identify cannabis use. Lighter or undisclosed marijuana use may not have been captured as a result. The observational design also cannot prove that cannabis use directly causes the outcomes observed. Even so, the findings held firm across sensitivity analyses, subgroups and time periods. That consistency adds real weight to the conclusion that cannabis use and diabetes management may not sit comfortably together, at least where cardiovascular and kidney health are concerned.

Source: dbrecoveryresources